Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q1 FY2021 Earnings Presentation
26 slides from Camlin Fine Sciences's earnings presentation, Aug 10, 2020
Slide 1: Intimation to BSE and NSE under SEBI LODR Regulation 30
11th August, 2020 To, To, BSE Limited, The Manager, 25, P. J. Towers, Listing Department, Dalal Street, National Stock Exchange of India Ltd., Mumbai – 400 001 Exchange Plaza, Bandra Kurla Complex, Ref: Company Scrip Code: 532834 Bandra (East), Mumbai‐ 400051 Ref: Symbol: CAMLINFINE || Series: EQ Su
Slide 2: Earnings Presentation Q1-FY21
EARNINGS PRESENTATION Q1-FY21
Slide 3: Executive Summary
2 Executive Summary 2 Company Overview Financials FY20 Consolidated (INR Mn) • Camlin Fine Sciences Limited (CFS), formed in 2006 after demerging the Operational fine chemical business from Camlin Ltd., is a vertically integrated company Revenue engaged in research, development, manufacturing, comme
Slide 4: Snapshot
3 Snapshot One of the few Leading Manufacturers of vertically and Antioxidants in the world 3rd largest producer of backward with more than 30 years of Vanillin in the world integrated players experience Serving more than 80 Preferred Partner for Strategic move to start countries with over manufactu
Slide 5: About the Company
4 About the Company • In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror Total Operational Revenue (INR Mn) shareholding) the fine chemical business from Camlin Ltd. • The Company has over 30 years of experience providing innovative solutions with a 12,000 10,491 competi
Slide 6: Q1-FY21 Financial Overview
5 Q1-FY21 FINANCIAL OVERVIEW
Slide 7: Q1-FY21 Financial & Operational Highlights
6 Q1-FY21 Financial & Operational Highlights Q1-FY21 Financial Highlights (Standalone): Q1-FY21 Financial Highlights (Consolidated): • Turnover: INR 1,212 Mn • Turnover: INR 3,057 Mn • EBITDA: INR 163 Mn • EBITDA: INR 510 Mn • EBITDA Margin : 13.45% • EBITDA Margin: 16.68% • Adjusted EBITDA*: INR 16
Slide 8: Q1-FY21 Standalone Income Statement (Ind-AS)
7 Q1-FY21 Standalone Income Statement (Ind-AS) Income Statement (Mn) Q1-FY21 Q1-FY20 Y-o-Y Q4-FY20 Q-o-Q Operational Revenue 1,212 1,436 (15.6)% 1,395 (13.1)% Total Expenses 1,049 1,308 (19.8)% 1,256 (16.5)% Operational EBITDA 163 128 27.3% 139 17.3% Operational EBITDA Margins (%) 13.45% 8.91% 454 B
Slide 9: Q1-FY21 Consolidated Income Statement (Ind-AS)
8 Q1-FY21 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) Q1-FY21 Q1-FY20 Y-o-Y Q4-FY20 Q-o-Q Operational Revenue 3,057 2,601 17.5% 2,929 4.4% Total Expenses 2,547 2,246 13.4% 2,586 (1.5)% Operational EBITDA 510 355 43.7% 343 48.7% Operational EBITDA Margins (%) 16.68% 13.65% 303 Bp
Slide 10: Country Overview
99 COUNTRY OVERVIEW
Slide 11: CFS India
10 CFS India • R&D Centre at Tarapur that has developed many new Diphenol-downstream products • Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries • Provides technical expe
Slide 12: Update on Dahej Project
11 Update on Dahej Project Work / Activities completed • Trial Runs were impacted due to the nationwide lockdown declared in March. • The plant was restarted on April 11, 2020, however operations remained impacted due to labour availability • The trials were again stopped due to the Blast in adjoini
Slide 13: CFS Mexico
12 CFS Mexico • Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016 • Primarily manufactures Blends and Additives • Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Cuba Pre-mix Mexico city Republic of • Total Market size is ~USD 200 Mn and CFS Mex
Slide 14: CFS Europe
13 CFS Europe Performance Chemicals • Acquired the manufacturing facility at Ravenna, Italy in 2011, which provides captive requirements of key raw materials i.e. Hydroquinone and Catechol • Capacity utilization achieved at 95% in FY19 • Considerable growth in EBITDA Margins & Profits due to favoura
Slide 15: CFS Brazil
14 CFS Brazil Shelf Life Solutions • Formed in 2013 for Blends and the production started in 2015 • Has an application lab in Indaiatuba – Brazil for customizing blends for Shelf-life Extension Solutions. • Handles distribution of bulk antioxidants and vanillin. Indaiatuba, Brazil • Key customer seg
Slide 16: CFS Wanglong
15 CFS Wanglong • CFS along with CFS Europe acquired 51% stake in Ningbo Wanglong Flavours in 2017 which had an operational plant since 2011 • This acquisition makes CFS the 3rd largest producer of Vanillin • Located in Grade 1 Industrial zone in the city of Yuyao Zhejiang Province, China. • It manu
Slide 17: CFS North America
16 CFS North America Shelf Life Solutions • Formed in October 2015 as a wholly owned subsidiary Market focus Iowa, USA • Food - Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants) • Pet food - Rendering for pet food (natural antioxidants), Rendering for animal feed (synthetic a
Slide 18: Historical Financial Overview
17 HISTORICAL FINANCIAL OVERVIEW
Slide 19: Historical Standalone Income Statement
18 Historical Standalone Income Statement Particulars (INR Mn) FY18 FY19 FY20 Q1-FY21 Operational Income 4,050 5,481 5,798 1,212 Total Expenses 3,996 5,182 5,201 1,049 EBITDA 54 299 597 163 EBITDA Margin 1.33% 5.46% 10.30% 13.45% Depreciation 91 91 113 31 Finance Cost 236 203 281 86 Other Income 92
Slide 20: Standalone Balance Sheet
19 Standalone Balance Sheet Particulars (INR Mn) FY19 FY20 Particulars (INR Mn) FY19 FY20 EQUITY 3,474 3,768 Non-Current Assets 2,733 3,802 a) Equity Share Capital 121 121 a) Property, Plant and Equipment 789 686 b) Other Equity 3,353 3,647 b) Capital Work In Progress 523 1,742 c) Non-Controlling In
Slide 21: Historical Consolidated Income Statement
20 Historical Consolidated Income Statement PARTICULARS (INR Mn) FY18 FY19 FY20 Q1-FY21 Operational Income 7,228 8,922 10,491 3,057 Total Expenses 7,073 8,235 9,184 2,547 EBITDA 155 687 1,307 510 EBITDA Margin 2.14% 7.70% 12.46% 16.68% Depreciation 267 290 328 95 Finance Cost 284 367 431 105 Other I
Slide 22: Consolidated Balance Sheet
21 Consolidated Balance Sheet PARTICULARS (INR Mn) FY19 FY20 PARTICULARS (INR Mn) FY19 FY20 EQUITY 4,303 4,601 Non-Current Assets 4,143 5,591 a) Equity Share Capital 121 121 a) Property, Plant and Equipment 2,055 2,034 b) Other Equity 3,588 3,910 b) Capital Work In Progress 573 1,761 c) Non-Controll
Slide 23: Consolidated Financial Highlights
22 Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) 12,000 10,491 1,500 12.46% 14.00% 10,000 8,922 12.00% 1,200 7,228 7.70% 10.00% 8,000 5,469 900 8.00% 6,000 5.16% 1,307 600 6.00% 4,000 687 2.14% 4.00% 2,000 300 282 155 2.00% - - 0.00% FY17 FY18 FY1
Slide 24: Capital Markets
23 Capital Markets 23 Share Price Data as on 30th June, 2020 55% 35% 15% -5% -25% -45% Jul-19 Aug-19 Sep-19 Oct-19 Nov-19 Dec-19 Jan-20 Feb-20 Mar-20 Apr-20 May-20 Jun-20 Camlin Fine Sciences SENSEX Price Data (30th June, 2020) INR Shareholding Pattern as on 30th June, 2020 Face Value 1.00 Market Pr
Slide 25: Disclaimer
24 Disclaimer 24 Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in
Slide 26: Thank You
25 Thank You
Camlin Fine Sciences — Q1 FY2021 Earnings Presentation on 6ix